Images List Premium Download Classic

Psychiatric

Psychiatric-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Heteroaryl-pyrimidinone compounds as pde2 inhibitors
October 04, 2018 - N°20180280390

The present invention is directed to substituted pyrimidinone compounds of formula (i) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (pde2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, parkinson's disease, parkinson's disease dementia (pdd), or huntington's disease, ...
Methods of treating depression
October 04, 2018 - N°20180280382

The present disclosure relates to methods of transitioning patients or obese patients being treated with vortioxetine to treatment with a monoamine oxidase inhibitor (maoi). The methods provided include delaying administration of the maoi for certain time periods after stopping administration of vortioxetine.
Methods of treating depression
October 04, 2018 - N°20180280381

The present disclosure relates to methods of transitioning patients or obese patients being treated with vortioxetine to treatment with a monoamine oxidase inhibitor (maoi). The methods provided include delaying administration of the maoi for certain time periods after stopping administration of vortioxetine.
Psychiatric Patent Pack
Download 117+ patent application PDFs
Psychiatric Patent Applications
Download 117+ Psychiatric-related PDFs
For professional research & prior art discovery
inventor
  • 117+ full patent PDF documents of Psychiatric-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Mecp2e1 gene
Centre For Addiction And Mental Health
September 20, 2018 - N°20180265926

The invention is a novel mecp2e1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders..
Cyclopropylmethanamines as selective 5-ht(2c) receptor agonists
The Board Of Trustees Of The University Of Illinois
September 20, 2018 - N°20180265453

Disclosed are 2-phenyl-cyclopropylmethanamines which are selective 5-ht(2c) receptor agonists and are used in the treatments of diseases and conditions wherein modulation of 5-ht(2c) receptors provides a benefit, such as obesity and psychiatric disorders.. .
Method for diagnosing psychiatric disorders
September 13, 2018 - N°20180259542

Disclosed herein is a method for predicting or diagnosing psychiatric disorders through analyzing skin tissues samples minimally invasive or non-invasively collected. The method disclosed herein makes it possible to diagnose psychiatric disorders through objective biomarkers at a very early age, without giving pain to subjects because of noninvasive or minimally invasive feature of skin sample collection method..
Psychiatric Patent Pack
Download 117+ patent application PDFs
Psychiatric Patent Applications
Download 117+ Psychiatric-related PDFs
For professional research & prior art discovery
inventor
  • 117+ full patent PDF documents of Psychiatric-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Oxy-cyanoquinolinone pde9 inhibitors
September 13, 2018 - N°20180258046

The present invention is directed to oxycyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (pde9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or huntington's disease, and those associated with striatal hypofunction or basal ganglia ...
Method for monitoring treatment of neuropsychiatric disorders
September 13, 2018 - N°20180256912

The present invention provides methods for monitoring neuropsychiatric treatment of depression and other disorders. The methods monitor the progress of neuropsychiatric treatment by examining electrical oscillations in the brain as measured by quantitative electroencephalography (qeeg).
Ursodeoxycholic acid and brain disorders
September 13, 2018 - N°20180256601

The present disclosure provides, among other things, uses for ursodeoxycholic acid or analogs or conjugates or derivatives thereof, for example for ameliorating the effects of brain disorders, neurodevelopmental disorders, and neuropsychiatric disorders, and compositions relating thereto.. .
Pyrimidinone amide compounds as pde2 inhibitors
September 13, 2018 - N°20180256575

The present invention is directed to pyrimidinone amide compounds which may be useful as therapeutic agents for the treatment of central nervous system and/or peripheral disorders associated with phosphodiesterase 2 (pde2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, alzheimer's, cognitive impairment, anxiety, depression, migraines, or huntington's ...
Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
September 13, 2018 - N°20180256517

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar ...
Clathrin therapeutic for neuropsychiatric diseases & disorders
September 13, 2018 - N°20180256511

The invention in suitable embodiments is directed to purified clathrin protein therapeutics. In one aspect, one or more purified clathrin protein therapeutic, formed in whole or in part from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more clathrin heavy chain protein and isoforms thereof, forms one or more type of therapeutic ...
Clathrin therapeutic for psychiatric disorders
September 13, 2018 - N°20180256510

The invention in suitable embodiments is directed to purified clathrin protein therapeutics. In one aspect, one or more purified clathrin protein therapeutic, formed in whole or in part from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more clathrin heavy chain protein and isoforms thereof, forms one or more type of therapeutic ...
Psychiatric Patent Pack
Download 117+ patent application PDFs
Psychiatric Patent Applications
Download 117+ Psychiatric-related PDFs
For professional research & prior art discovery
inventor
  • 117+ full patent PDF documents of Psychiatric-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
(r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2...
Bristol-myers Squibb Company
September 06, 2018 - N°20180250316

The disclosure generally relates to compounds of formula i, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nr2b nmda receptor and may be useful for the treatment of various disorders of the central nervous system..
Exo-s-mecamylamine formulation and use in treatment
University Of South Florida
September 06, 2018 - N°20180250244

A pharmaceutical composition includes a therapeutically effective amount of exo-s-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-r-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg.
Triazolyl pyrimidinone compounds as pde2 inhibitors
Merck Sharp & Dohme Corp.
August 23, 2018 - N°20180237422

The present invention is directed to pyrimidine carboxamide compounds of formula i which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (pde2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, parkinson's disease, parkinson's disease dementia (pdd), or huntington's disease, ...
Triazole derivatives
August 23, 2018 - N°20180237401

The compounds of formula i may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.. .
Methods for determining the risk of a systemic lupus erythematosus (sle) patient to develop neuropsychiatric ...
Immunarray Ltd
August 16, 2018 - N°20180231565

Methods and kits are provided for diagnosing of neuropsychiatric syndromes concurrent with sle (npsle) and for determining whether an sle subject is at risk of developing a neuropsychiatric disease.. .
Methods and compositions for biomarkers of depression and pharmacoresponse
August 16, 2018 - N°20180230536

The present invention relates to a method of diagnosing depression (even at an early stage that may precede clinical symptoms), for determining the pharmacoresponse to antidepressants, for managing treatment of psychiatric disorders, including depression, and for treatment of depression in patients. Further provided is a method for screening antidepressants..
Means and methods for the diagnosis and treatment of neuropsychiatric diseases
Charite-universitatsmedizin Berlin
August 16, 2018 - N°20180230432

The present invention is related to a bone marrow-derived myeloid progenitor cell (mpc), preferably an isolated bone marrow-derived myeloid progenitor cell (mpc), wherein the bone marrow-derived myeloid progenitor cell (mpc) is expressing cd34, c-kit (cd117) and cx3cr1.. .
Co-crystals of substituted glycine and uses thereof
August 16, 2018 - N°20180228754

Compositions comprising such, and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, suicidal ideation and/or behavior, obsessive compulsive disorder or alzheimer's disease). Also provided herein are methods for preparing the co-crystals..
Loading